Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease

  • Yuyang Ze
  • Fei Shao
  • Xuefeng Feng
  • Shanmei Shen
  • Yan Bi
  • Dalong Zhu
  • Xiaowen Zhang
Publication date
December 2022
Publisher
Springer Science and Business Media LLC
Journal
BMC Endocrine Disorders

Abstract

Abstract Liver dysfunction is a common complication of Graves’ disease (GD) that may be caused by excessive thyroid hormone (TH) or anti-thyroid drugs (ATDs). Radioactive iodine (RAI) therapy is one of the first-line treatments for GD, but it is unclear whether it is safe and effective in patients with liver dysfunction. 510 consecutive patients with GD receiving first RAI were enrolled in the study, and followed up at 3-, 6- and 12-month. Liver dysfunction was recorded in 222 (43.5%) patients. GD patients with liver dysfunction had higher serum levels of free triiodothyronine (FT3) (median 27.6 vs. 20.6 pmol/L, p < 0.001) and free thyroxine (FT4) (median 65.4 vs. 53.5 pmol/L, p < 0.001) levels than those with normal liver function. Binary ...

Extracted data

We use cookies to provide a better user experience.